Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of MORAb-009 in Patients With Solid Tumor

This study has been completed.
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. ) Identifier:
First received: November 23, 2009
Last updated: January 19, 2016
Last verified: January 2016
MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose.

Condition Intervention Phase
Drug: MORAb-009
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Study of MORAb-009 in Patients With Solid Tumor

Resource links provided by NLM:

Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • To investigate dose-limiting toxicity and estimate maximum tolerated dose. [ Time Frame: 4 Weeks ]

Secondary Outcome Measures:
  • The best overall response rate in the RECIST evaluation and the preliminary evaluation calculating the frequency of Completed response and Partial Response. [ Time Frame: During Study ]

Enrollment: 17
Study Start Date: November 2009
Study Completion Date: February 2013
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MORAb-009 Drug: MORAb-009
MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.


Ages Eligible for Study:   20 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria;

  1. Japanese male and female patients aged from 20 to less than 80 years at obtaining informed consent
  2. Patient with histologically or cytologically diagnosed solid tumor
  3. Patient who is mesothelin-positive confirmed by immunohistochemistry (IHC) (except for pancreatic cancer and mesothelioma that mesothelin-positive is frequently reported)
  4. Patient with solid tumor who is non responder to or resistant to standard therapy and has no other appropriate treatment
  5. Performance Status (PS) is 0 to 1 by Eastern Cooperative Oncology Group ECOG criteria

Exclusion criteria

  1. Brain metastasis presenting clinical symptoms or requiring medical treatment
  2. Serious and systemic infection requiring medical treatment
  3. History of hypersensitivity to protein formulations including monoclonal antibody
  4. With active multiple carcinoma (except for carcinoma in situ and intramucosal carcinoma)
  5. With celomic fluid (pleural effusion or ascites) uncontrolled by drainage, or with a large volume of celomic fluid
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01018784

Sayama-shi, Osaka, Japan
Sponsors and Collaborators
Eisai Co., Ltd.
Study Director: Chifumi Kitamura Morphotek Clinical Development Section, JAC PCU
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Eisai Co., Ltd. Identifier: NCT01018784     History of Changes
Other Study ID Numbers: MORAB-009-J081-102
Study First Received: November 23, 2009
Last Updated: January 19, 2016

Keywords provided by Eisai Inc.:

Additional relevant MeSH terms:
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on May 22, 2017